Evaluation of zinc sulfate as an adjunctive therapy in COVID-19 critically ill patients: a two center propensity-score matched study

Table 2 Regression analysis for ICU complication (s) after PS matching

Outcomes	Crude analysis		P-value^^	Odds Ratio (OR) (95%CI)	P-value*^
Outcomes	Control	Zinc	P-value^^	Odds Ratio (OR) (95%CI)	P-value*^
Acute kidney injury, n (%)^§	25 ( 31.3)	10 ( 15.4)	0.02^^	0.46 (0.19, 1.06)	0.07
Liver injury, n (%)^§	7 ( 8.8)	2 ( 2.5)	0.08**	0.24 (0.05, 1.26)	0.09
Thrombosis/infraction, n (%)^§	7 ( 8.8)	3 ( 3.8)	0.19**	0.46 (0.11, 1.98)	0.29
Respiratory failure requiring MV, n (%)^$*	9/26 (34.6)	9/27 (33.3)	0.92^^	0.98 (0.31, 3.14)	0.98

^§After zinc initiation
^$*Denominator of the percentage is non-mechanically ventilated patients with 24 h of ICU admission
^^Chi-square /**Fisher Exact test is used to calculate the P-value
^*^Multivariable logistic regression analysis is used to calculate Odds ratio and p-value

ISSN: 1364-8535